am 580 has been researched along with Angiogenesis, Pathologic in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oikawa, T | 1 |
| Okayasu, I | 1 |
| Ashino, H | 1 |
| Morita, I | 1 |
| Murota, S | 1 |
| Shudo, K | 1 |
1 other study available for am 580 and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo.
Topics: Animals; Benzoates; Cell Differentiation; Chick Embryo; Dose-Response Relationship, Drug; Neovascula | 1993 |